Re: the melanoma question (news out today about the success
Re: the melanoma question (news out today about the success of Moderna/Merck mRNA vaccine vs melanoma), someone on Reddit/Livimmune named "AggieEC3" posted this 4 months ago concerning the possible efficacy of Leronlimab vs melanoma:
"CCR5 is expressed in melanoma. The cold tumor problem exists there too. A meaningful portion of melanoma patients don't respond to checkpoint inhibitors even though Keytruda is already an approved standard of care in that indication. If leronlimab's Prime and Pair mechanism converts cold tumors to hot on demand, melanoma is exactly the kind of indication where that capability would matter most.
And the market context is hard to ignore. The U.S. spends $8.9 billion annually treating skin cancer, with melanoma driving a significant share of that burden. ICIs already account for 44% of melanoma spending among Medicare patients. The reimbursement infrastructure is already there. The annual cost of treating newly diagnosed melanoma cases alone is projected to reach $1.6 billion by 2030.
None of this is to get ahead of where the data actually is. ESMO in October is the moment that matters. The confirmed ORR needs to come in. Everything has to replicate at scale. I'm not suggesting melanoma is next on the timeline. I'm asking whether the biology points there if the mechanism continues to hold.
Dr. Lalezari mentioned two undisclosed solid tumor ITTs in development with updates expected this summer. Whether melanoma is one of them I don't know. But it fits the profile almost perfectly."
Thank you, AggieEC3, whoever you are. And let's hope Cytodyn gets its chance in the melanoma octagon vs Merck/Moderna!
At the very least, it appears we'd be cheaper.
12
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...
Continue Reading
A Pre-Dawn Labor Test Is Brewing in Georgia At 2:30 in the morning, nobody gathers outside a distribution center for the scenery. More than 100 Pepsi-Cola drivers from Atlanta and Lithonia are slated to meet Tuesday, November 24, at the Pepsi Distribution Center in Lithonia, Georgia, with Teamsters General President Sean M. O'Brien joining them. That hour matters. It puts...
Continue Reading
A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...
Continue Reading
A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...
Continue Reading
Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...
Continue Reading
Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...
Continue Reading
GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...
Continue Reading
Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...
Continue Reading
Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...
Continue Reading
A 1.8-kilogram box may not sound like much, but it captures where household solar is trying to go: smaller, less intimidating, and far easier to put to work. At RE+ 2026 in Las Vegas, Hoymiles laid out a residential lineup spanning plug-in solar, battery storage and conventional rooftop microinverters. This was not one flashy gadget looking for applause. It was a fairly...
Continue Reading
Top 5 Most Recently Viewed Articles
Successful Results from Hydreight Technologies Inc.'s Annual Meeting Hydreight Technologies Inc. (TSXV: NURS, OTC: HYDTF, FSE: SO6) proudly shares the positive outcomes from their recent Annual General Meeting. Conducted virtually, the meeting brought together shareholders who actively participated in decision-making. Shareholder Voting Outcomes During this significant...
Continue Reading
Anusia Gillespie's Soul Toll: A Unique Literary Journey Soul Toll is gaining significant recognition for its imaginative storytelling which straddles the realms of ambition and awakening. This debut novel by Anusia Gillespie is becoming a staple not just in libraries, but also in yoga studios and leadership circles. Recognition from Kirkus Reviews The November issue of...
Continue Reading
The Challenge of Buying a Home in Stillwater Walking into Stillwater's housing market as a first-time buyer is like stepping onto a high-wire act. You're balancing dreams with dollars, all while the ground beneath you keeps shifting. What stands out from HelloNation's deep dive into this market, featuring Page Provence of Fisher Provence Realtors Inc., is that knowledge...
Continue Reading
Outstanding Achievement in Catholic Journalism The National Catholic Reporter (NCR) and its affiliated platforms, such as Global Sisters Report (GSR) and EarthBeat, have recently achieved remarkable recognition in the realm of Catholic media. With over 70 awards at the prestigious Catholic Media Awards, NCR has reaffirmed its dedication to delivering independent...
Continue Reading
Centessa Pharmaceuticals' Upcoming Investor Conferences Centessa Pharmaceuticals plc (Nasdaq: CNTA), a pioneering clinical-stage pharmaceutical company, is set to mark its presence in several prominent investor conferences. The company's mission is to discover and develop transformative medicines aimed at enhancing patient outcomes. Guggenheim Healthcare Innovation...
Continue Reading